Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025
Biomea Fusion, Inc. is back in the spotlight after the company reported long‑term data showing that its experimental diabetes drug icovamenib can deliver durable blood‑sugar control many months after patients stop taking it. The new results, presented at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease in Los Angeles, pushed Biomea Fusion’s stock higher on Friday and have reignited debate over whether this beaten‑down biotech could still be a high‑risk turnaround story. Nasdaq+1 As of Friday, December 5, Biomea Fusion shares were trading in the low‑$1 range, giving the company a market capitalization of roughly $70–80 million – a tiny valuation compared with the multibillion‑dollar markets it is targeting in type 2 diabetes and obesity.Stock Titan+1 Despite the modest bounce, the stock remains down around 80% over the past year and roughly 70% year‑to‑date, reflecting a long slide from 2023–2024 highs. Investing.com+1
